AdCure Bio

AdCure Bio is a private pre-clinical oncology biotech developing intravenously delivered immuno-stimulatory oncolytic adenoviruses for solid tumors and metastatic cancers. The company is focused on viro-immunotherapy approaches designed to selectively infect and kill tumor cells while also stimulating anti-tumor immunity. Its core technology is the AVID platform, described as Artificial Vectors for Intravascular Delivery, which is engineered to reduce liver sequestration and enable systemic delivery of oncolytic adenoviruses. AdCure Bio highlights late-stage, disseminated, and non-resectable cancers that are refractory to existing treatments, with particular emphasis on lung cancer. Publicly identified pipeline assets include AVID-212 and AVID-388, both in preclinical development.